Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Randal Bowlin

Family Medicine Conway, AR Medical Doctor

NPI 1265419774 CMS profile 328993

2425 Dave Ward Dr, Ste 401, Conway, AR 72034

Open in the dashboard

General payments

$11,253

877 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$652,150

6 holdings reported · through program year 2025

Through program year 2025, Randal Bowlin of Conway, AR is reported in the CMS Open Payments database as having received $11,253 across 877 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $652,150 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $169 8
2024 General $142 8
2023 General $1,996 153
2022 General $2,204 168
2021 General $2,520 203
2020 General $2,048 155
2019 General $2,173 182
2025 Ownership $4,462 2
2024 Ownership $201,390 1
2023 Ownership $201,389 1
2022 Ownership $122,452 1
2021 Ownership $122,457 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Randal Bowlin
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Randal Bowlin were reported at $169. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Randal Bowlin Family Medicine median Middle half National median
2019 $2,173 $150 $41–$543 $163
2020 $2,048 $120 $32–$415 $114
2021 $2,520 $137 $35–$551 $132
2022 $2,204 $137 $37–$512 $149
2023 $1,996 $149 $42–$545 $160
2024 $142 $156 $44–$560 $164
2025 $169 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,299 86 payments
  2. GlaxoSmithKline, LLC. $1,009 137 payments
  3. AstraZeneca Pharmaceuticals LP $914 38 payments
  4. Lilly USA, LLC $794 70 payments
  5. AbbVie, Inc. $650 60 payments
  6. Astellas Pharma US Inc $471 21 payments
  7. Pfizer Inc. $463 46 payments
  8. Amarin Pharma Inc. $450 31 payments
  9. Abbott Laboratories $439 38 payments
  10. Amgen Inc. $419 27 payments
  11. Other $4,344 323 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,051 872 payments
  2. Education $202 5 payments
Products named General payments · program years 2019–2025
  1. Ozempic $979 64 payments
  2. TRELEGY ELLIPTA $728 105 payments
  3. RYBELSUS $701 47 payments
  4. FARXIGA $657 18 payments
  5. NURTEC ODT $430 42 payments
  6. Vascepa $425 29 payments
  7. TRULICITY $390 30 payments
  8. FreeStyle Libre $367 33 payments
  9. SYMBICORT $352 10 payments
  10. XARELTO $296 24 payments
  11. Other $10,075 751 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

889

Median for Family Practice: 1,826

Drug cost

$43,828

Median for Family Practice: $120,094

Branded share of claims

13.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 15 $13,684
Ozempic Semaglutide Brand 14 $13,667
Eliquis Apixaban Brand 13 $7,374
Tamsulosin Hcl Generic 40 $774
Atorvastatin Calcium Generic 100 $756
Gabapentin Generic 26 $635
Pantoprazole Sodium Generic 39 $534
Omeprazole Generic 65 $493
Potassium Chloride Generic 21 $492
Losartan Potassium Generic 65 $482

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
$22 — —
Veozah
$22 — —
REXULTI
$22 — —
XYOSTED
$21 — —
GIVLAARI
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

877 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record